In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Hexarelin | ||
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Small molecule | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 1,112 | 411 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 21 (13 in people) | 14 (12 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 14 · 5 active | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Hexarelin | MK-677 (ibutamoren) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 3692708910 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
| Stress hormonesEndocrine and hormones | 87843 | 241311 |
|---|
| Pituitary hormonesEndocrine and hormones | 6464 | 8323 |
|---|
| Heart functionEndocrine and hormones | 151199141 | 77 |
|---|
| Receptor activity and mechanismPharmacology | 105123801 | 561244 |
|---|
| Bone and jointMusculoskeletal | 286193 | 2222 |
|---|
| PharmacokineticsPharmacology | 5052916 | 292189 |
|---|
| LipidsMetabolic and weight | 151113 | 21192 |
|---|
| Glycemic controlMetabolic and weight | 153111 | 13112 |
|---|
| Exercise and physical functionMusculoskeletal | 615 | 1111 |
|---|
| Adverse eventsWhole body | 22 | 99 |
|---|
| Body compositionMetabolic and weight | 22 | 99 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Hexarelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Hexarelin | MK-677 (ibutamoren) |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: difference from placebo, in ng/ml | No comparable result 54 randomized-trial results measure it in another way or another unit. | 34.42 to 68.44 ng/ml 95% confidence interval for IGF-1 difference Dose studied: 25mg/day24 weeksn = 1232011 |
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in p value | No comparable result 1 randomized-trial result measure it in another way or another unit. | < 0.05 p value P value for Serum leptin, MK-677 versus placebo at 2 weeks Dose studied: 25 mg/day8 weeksn = 241999 |
| Stress hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in ng/l x 125 min | 3444 ng/L x 125 min ACTH AUC n = 151999 | No comparable result 10 randomized-trial results measure it in another way or another unit. |
| Pituitary hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in pg/ml | 30.3 pg/ml ACTH peak Dose studied: 2.0 microg/kgn = 62001 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Exercise and physical functionMusculoskeletalCompared as: difference from placebo, in w | No randomized trial result 6 results from other study designs. | 12.5 W Mean stair climbing power difference Dose studied: 25mg/day24 weeksn = 1232011 |
| Bone and jointMusculoskeletalCompared as: difference from placebo, in p value | No randomized trial result 28 results from other study designs. | < 0.001 p value P value for Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects Dose studied: 5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks9 weeksn = 911999 |
| Body compositionMetabolic and weightCompared as: value in the arm that got the peptide, in kg | No randomized trial result 2 results from other study designs. | 1.1 kg Fat-free mass change · MK-677 Placebo: −0.5 kg Dose studied: 25 mg once daily1 yearn = 652008 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | No randomized trial result 11 results from other study designs. | 2.7 kg Body weight change · MK-677 Placebo: 0.8 kg Dose studied: 25 mg once daily1 yearn = 652008 |
| LipidsMetabolic and weightCompared as: difference from placebo, in p value | No randomized trial result 15 results from other study designs. | < 0.001 p value P value for Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks Dose studied: 25 mg daily8 weeksn = 241999 |
| Sex hormones and fertilityEndocrine and hormonesCompared as: difference from placebo, in unitless | No randomized trial result 6 results from other study designs. | −< 0.05 unitless P value for total testosterone reduction · Shown as a change. The study reports a p value for total testosterone reduction of this size. Dose studied: 25 mg/day8 weeksn = 241999 |
| Thyroid functionEndocrine and hormonesCompared as: difference from placebo, in p value | No randomized trial result 4 results from other study designs. | < 0.05 p value P value for Serum free T3, MK-677 versus placebo at 8 weeks Dose studied: 25 mg/day8 weeksn = 241999 |
| SleepSleepCompared as: difference from placebo, in p | No randomized trial result 2 results from other study designs. | < 0.03 p p value for Deviations from normal sleep in young adults Dose studied: 25 mg7 daysn = 81997 |
No comparable result
54 randomized-trial results measure it in another way or another unit.
34.42 to 68.44 ng/ml
95% confidence interval for IGF-1 difference
Dose studied: 25mg/day24 weeksn = 1232011
No comparable result
1 randomized-trial result measure it in another way or another unit.
< 0.05 p value
P value for Serum leptin, MK-677 versus placebo at 2 weeks
Dose studied: 25 mg/day8 weeksn = 241999
3444 ng/L x 125 min
ACTH AUC
n = 151999
No comparable result
10 randomized-trial results measure it in another way or another unit.
30.3 pg/ml
ACTH peak
Dose studied: 2.0 microg/kgn = 62001
No comparable result
2 randomized-trial results measure it in another way or another unit.
No randomized trial result
6 results from other study designs.
12.5 W
Mean stair climbing power difference
Dose studied: 25mg/day24 weeksn = 1232011
No randomized trial result
28 results from other study designs.
< 0.001 p value
P value for Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
Dose studied: 5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks9 weeksn = 911999
No randomized trial result
2 results from other study designs.
1.1 kg
Fat-free mass change · MK-677
Placebo: −0.5 kg
Dose studied: 25 mg once daily1 yearn = 652008
No randomized trial result
11 results from other study designs.
2.7 kg
Body weight change · MK-677
Placebo: 0.8 kg
Dose studied: 25 mg once daily1 yearn = 652008
No randomized trial result
15 results from other study designs.
< 0.001 p value
P value for Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks
Dose studied: 25 mg daily8 weeksn = 241999
No randomized trial result
6 results from other study designs.
−< 0.05 unitless
P value for total testosterone reduction · Shown as a change. The study reports a p value for total testosterone reduction of this size.
Dose studied: 25 mg/day8 weeksn = 241999
No randomized trial result
4 results from other study designs.
< 0.05 p value
P value for Serum free T3, MK-677 versus placebo at 8 weeks
Dose studied: 25 mg/day8 weeksn = 241999
No randomized trial result
2 results from other study designs.
< 0.03 p
p value for Deviations from normal sleep in young adults
Dose studied: 25 mg7 daysn = 81997
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Hexarelin found in ClinicalTrials.gov.
Top 3 of 14 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 not yet recruiting · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Lumos Pharma150 participants20 May 2026 to est. Jan 2028
Growth Hormone Deficiency (GHD)
Lumos Pharma150 participantsest. Feb 2027 to est. Feb 2030
Growth Hormone Deficiency (GHD)
Lumos Pharma104 participants31 Dec 2020 to 4 Sept 2024
Growth Hormone Deficiency